Rhapsido (remibrutinib) - Novartis
Topical Remibrutinib Attenuates LL37-Induced Rosacea-Like Dermatitis by Inhibiting BTK Activation, NF-κB Signaling and Mast Cell Activation. (PubMed, J Inflamm Res) - Oct 20, 2026 - "BTK and NF-κB are involved in LL37-induced, IgE-independent mast cell activation and rosacea-like inflammation. Topical remibrutinib attenuated experimental rosacea-like dermatitis by inhibiting BTK phosphorylation and NF-κB activation and mast cell activation, supporting topical BTK inhibition as a potential therapeutic strategy for rosacea." 
Journal • Dermatitis • Dermatology • Immunology • Inflammation • Rosacea
http://www.ncbi.nlm.nih.gov/pubmed/42894756
 
Chengqi Liu; Dong Zhang; Hua Liu; Huiping Fan; Qingsong Ma; Wangchao Li; Weiyuan Ma
 
Oct 20, 2026
 
Prev Next